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Encorton) with typing HPV 6,16 which were previously 
detected in anogenital region of the patients. 
One hundred recipients (20-65 aged) 0.5-18 years 
after allotransplantation were assessed clinically and 
histologically including biopsy of oral mucous and PCR 
techniques for HPV identification. Primers specific for 
E4 (HPV 6) and E6 (HPV 16) ORF were used for the 
amplification of HPV DNA present in samples. 
Epithelial verrucas differentiated in size, morphology 
and placement were found clinically in 10% patients. 
Thick, acantotic changed epithelium with numerous 
coilocytes and clear hiperproliferation was revealed in 
samples taken 
from all patients with the viral infection.Type 16 HPV 
were detected in 24% (24/100) of the recipients, type 6 
HPV occurred in 5% (5000) while both 16 HPV and 6 
HPV were revealed in 3 patients only. 
Our data indicate that the recipients with decreased 
immune response, the HPV infection and the chronic 
immunosuppression are at a major risk for the develop- 
ment of the oral neoplasm proliferations. The long term 
follow-up for detection of the oncogenic virus type as 
well as monitoring of the level of the immunosup- 
pression should be undertaken for protection against the 
development of the oral cancer in the kidney recipients. 
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The aim of this study was to assess the data related to 
human cytomegalovirus (HCMV) of renal transplant 
recipients in our transplantation center. Between April 
2000 and March 2002,109 consecutive renal transplants 
(53 cadaveric, 56 living-related) were performed in our 
center. All the donors and recipients were HCMV 
seropositive (D +/R+). Living-related recipients received 
prednisolonelmycophenolate mofetil cyclosporine or 
tacrolimus as an immunosuppressive regimen. Cadaveric 
recipients received the same triple therapy plus poly- 
clonal antibody for 7 to 14 days as induction. Polyclonal 
antibody therapy was also given in acute vascular or 
clinically severe rejection episodes. In all patients, 
acyclovir or valaciclovir was given as a prophylactic 
treatment for six months. Evidence of HCMV infection 
was monitored by HCMV antigenemia assay weekly 
for three months, biweekly for 3-6 months and then 
monthly up to one year after transplantation. HCMV 
antigenemia was positive (median: 6.5/2X lo5 PBL, 
range: 1-924/2x lo5 PBL) in 50 of 109 (45%) recipients 
(cadaveric: 41%, living-related: 16%). The median time 
for first positive antigenemia was 54 (3-145) days. 
Seventeen of the 31 antigenemia positive recipients had 
high level antigenemia (250/2x 10” PBL) and six of 
them developed HCMV disease (p<O.OOl). Twenty-six 
of 31 patients received ganciclovir for 20.4k2.7 days. 
HCMV infection and disease rates were higher in 
cadaveric recipients (p<O.OOl, p=O.O8, respectively). 
The risks of leucopenia and increment in transaminase 
levels were higher if first antigenemia level was high 
(p=O.O34, p=O.O14, respectively). HCMV infection and 
disease have been seen more frequently in thymo- 
globulin receiving patients than in ATG group (Thymo- 
globulin:5/6, ATG:l/B). Acute rejection rate was higher 
in HCMV antigenemia positive recipients than in 
negative recipients (28% vs. 13%; p=O.O61). Four of six 
recipients (12%) who have the disease died due to 
HCMV in the follow-up period. Our results suggested 
that polyclonal antibody treatment increases the rate of 
HCMV infection. We believe that monitoring of HCMV 
infection by antigenemia assay is a reasonable procedure 
and if antigen level is higher than r50/2x105 PBL, 
ganciclovir must be initiated, especially in recipients 
with leucopenia and high transaminase levels. 
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During the first two decades after 1958 when Anstrom 
et al first identified promyelocytic leukemia (PML), there 
were fewer than 100 pathologically confirmed cases of 
the disease. The diagnosis was most likely to be found in 
association with hematologic malignancies. With the 
onset of the HIV/AIDS epidemic the number of cases 
of PML escalated and the diagnosis became a relative 
frequent and important consideration in patients with 
advanced immunosuppression. In the summer of 2001 a 
33-year-old female patient with a subacute presentation 
of motor deficits was transferred to our hospital. 
The patient had a 6-month history of progressive 
motor deficits with periodic attenuation but without 
return to base line function. At admission she was bed 
bound without movement of her left extremities and of 
her right lower extremity. A month before admission she 
had been in rehabilitation ambulating and performing 
her own activities of daily living. She had a cushingoid 
appearance. Over the prior 6 months serial CT and MRI 
brain scans had shown lesions reported to represent 
cerebrovascular accidents. She had a history of SLE 
diagnosed when she was 6 years old. In 1979 the diag- 
nosis was confirmed by renal and skin biopsies. Through- 
out childhood and adolescence she had received 
symptomatic relief with prednisone therapy. In the late 
winter of 2000 she had exacerbations of symptoms 
attributed to SLE and been treated with prednisone in 
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doses up to 100 mg per day with second drug therapy of 
azathioprine or alternatively cyclophosphamide. After 
the transfer to our hospital a plethora of laboratory 
studies for rheumatologic, inflammatory, and infectious 
processes where obtained and except for a very modest 
decrease in C4 all where normal. A further contrast 
enhanced MRT of the brain showed extensive right- 
sided white matter disease with significant extension into 
the left hemisphere. An HIV ELISA, a CD4 count, and 
a JC virus PCR were obtained.The ELISA was negative; 
but the CD4 count was 52 and JCV-VL was 2888 
copies/ml (normal ~80). An exhaustive literature search 
revealed minimal therapeutic options for the JC virus 
infection, and the patient was discharge to hospice in the 
care of her physician on a suggested regimen of 
a prednisone taper, and hopefully therapeutic alpha- 
interferon and cidofovir treatment. As of February 2002 
the patient remains bed bound. 
This devastating case of JC virus infection illustrates 
the confounding diagnostic dilemmas frequently encoun- 
tered by practitioners. In this instance a consistent 
explanation is found with the realization that the patient 
probably suffers from advanced iatrogenic immuno- 
suppression and the resultant possible opportunistic in- 
fections. 
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Objective: Valacyclovir 2g four times daily for 90 days 
has been shown (Lowance et al., NEJM 1999: 340:1462- 
70) to reduce the incidence of cytomegalovirus (CMV) 
infection and disease and acute graft rejection (GR) at 
six months vs placebo after renal transplantation. Among 
the CMV seropositive patients (R+) the incidence of 
CMV disease was reduced from 6% to 1% and there was 
a reduction in biopsy confirmed acute GR from 36% 
to 30%. CMV disease was significantly reduced in the 
donor-positive recipient-negative (D+R-) group from 
45% to 16% and rate of biopsy confirmed acute GR 
from 52% to 26% compared to placebo. This retro- 
spective review of patients’ medical notes was designed 
to assess whether the benefits extend to increased graft 
function and survival during 5 years follow-up. 
Methods: Data were available for 449 of the 616 patients 
enrolled in the original study, P66/H73-012. The primary 
population for analysis was the ITT population of all 
patients randomised in the original study. The primary 
endpoint was time to allograft failure up to 5 years post- 
transplant. Rates of acute GR, chronic GR, CMV disease 
and survival were secondary endpoints. 
Results: No significant treatment difference was 
observed for time to allograft failure in either the R+ or 
D+R- patients although the benefits in preventing 
CMV disease and acute GR are still evident at 5 years. 
fR+) (D+R-J 
Val PBO Val PBO 
Endpoint n=204 n=204 HR n=106 n=l02 HR 
Allograft failure 28 23 1.29 25 24 0.91 
Acute GRa 39 41 0.91 36 55 0.52* 
Chronic GRa 28 16 1.86** 24 30 0.67 
fvavkeaseb 2 8 11 6 0.28* 6  15 7 43 16 0.22* .43 
*Statistically significant in favour of valaciclovir. **Statistically significant 
in favour of placebo. 
aBiopsy confirmed graft rejection. bLaboratory confirmed graft rejection. 
Conclusions: The benefit of 90 days treatment with 
valacyclovir in preventing acute GR in D+R- patients 
is still apparent at 5 years post-transplant. A trend to 
increased patient survival with valacyclovir in the high- 
risk D+R- patients is noted. 
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Confirmatory diagnosis of reactivated human cyto- 
megalovirus (HCMV) infections can only be made by 
culturing the virus in cell culture, or alternatively by 
detecting its antigen or its nucleic acids using amplifica- 
tion techniques. It is necessary because presence of IgM 
antibodies is not a reliable method of viral replication 
and does not correlate well with disease manifestations. 
Detection of HCMV DNA in clinical specimens is 
considered a cornerstone in the diagnosis of CMV 
disease. For amplifying the specific CMV DNA nested 
polymerase chain reaction (nPCR) is reported to higher 
specificity. Therefore, we carried out a study to compare 
the usefulness of nested PCR vis-a-vis commonly used 
u-capture enzyme linked immunosorbent assay (mac- 
ELISA) in renal and bone marrow transplant patients 
with clinical manifestations suggestive of post-transplant 
CMV reactivation. A total of 49 blood specimens were 
collected from 19-bone marrow and 30 renal transplant 
patients. All the samples were subjected to IgG, IgM 
ELISA and Nested PCR assay. The age of our patients 
ranged from 18 to 50 years (mean age 32+17). Most of 
our patients were males (44) while only 5 were females. 
All of the 49 patients were found positive for anti-CMV 
IgG antibodies (100%) and only 22.45% were IgM 
positive. Where as, nPCR was positive in 69.38% of 
cases. All PCR positive patients responded to anti-CMV 
therapy. Hence, this study concluded that the nested 
PCR is more sensitive as well as specific in symptomatic 
transplant cases and must be carried out at all transplant 
